Genovate Aims For Global Insulin Position Under $1bn Project
This article was originally published in PharmAsia News
Executive Summary
Genovate has begun construction of its first manufacturing facility for insulins as part of a total investment of $1bn and with the ambition to become China’s first, and the world's fourth largest, manufacturer of insulin using efficient and ecologically friendly production technology.